Assessment of the Presence of the SARS-COV-2 Virus in the Peritoneum of

Status Completed

Clinical Trial Summary

The purpose of this study is to determine whether the virus SARS-CoV-2, responsible for the disease COVID-19, is present in the abdominal cavity during emergency laparoscopic exploration in confirmed or suspected COVID-19 patients.

Clinical Trial Description

A new human coronavirus responsible for pneumonia, SARS-CoV-2, emerged in China in December 2019 and has spread rapidly worlwide. COVID-19, the disease caused by this virus, has a very polymorphous clinical presentation, which ranges from upper respiratory tract infections to acute respiratory distress syndrome. Research institutions are working restlessly to elucidate the physiopathology of COVID-19 to develop new and more efficacious strategies on diagnosis, treatment and prevention planning. However, many aspects of the disease process are still unknown. Despite the lack of complete understanding of COVID-19, recommandations from world health authorities to surgical societies have been published in order to prevent viral transmission within the hospital setting. Concerning prevention of viral transmission during laparoscopy on confirmed or suspected COVID-19 cases, strict measures were taken to protect surgical and anesthesia staff. These recommandations are mainly based on avoiding leak of pneumoperitoneum during surgical exploration as it may represent a potential source of viral transmission, eventhough there is no scientific evidence on it. The lack of evidence of this mode of transmission makes difficult to develop more appropriate and efficacious recommandations. This study is designed to assess for the presence of SARS-CoV-2 virus in the peritoneal serosa during emergency laparoscopy on confirmed or suspected COVID-19 cases. During laparoscopic surgical exploration, 3 samples of pneumoperitoneum will be taken in 3 standardized steps of the procedure. Two more other samples of peritoneal effusion or peritoneal lavage (in the absence of peritoneal effusion) and bile (if cholecystectomy is performed) will also be collected. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04361396
Study type	Interventional
Source	Centre Hospitalier René Dubos
Contact
Status	Completed
Phase	N/A
Start date	June 16, 2020
Completion date	January 18, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04369456` - Blood Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Kidney Transplant Patients	N/A
Completed	`NCT04527471` - Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19	Phase 2
Recruiting	`NCT04410510` - P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19	Phase 2/Phase 3
Withdrawn	`NCT04383899` - Role of Ibuprofen and Other Medicines on Severity of Coronavirus Disease 2019
Completed	`NCT04542915` - COVID-19-Related Health and Practices Among Dental Hygienists
Not yet recruiting	`NCT04400019` - Prevention of COVID19 Infection in Nursing Homes by Chemoprophylaxis With Hydroxychloroquine (PREVICHARM)	Phase 2/Phase 3
Terminated	`NCT04954014` - Pilot Study of Single Dose Bevacizumab as Treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients	Phase 2
Completed	`NCT04532632` - Taste and Smell Impairment in Critically Ill COVID-19 Patients
Suspended	`NCT04385771` - Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation	N/A
Terminated	`NCT04530448` - Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization	Phase 4
Completed	`NCT04413435` - Clinical Characteristics of Critically Ill Patients With COVID-19
Terminated	`NCT05593770` - International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response	Phase 2/Phase 3
Completed	`NCT04510493` - Canakinumab in Patients With COVID-19 and Type 2 Diabetes	Phase 3
Active, not recruiting	`NCT04587219` - The Study of "Gam-COVID-Vac" Vaccine Against COVID-19 With the Participation of Volunteers of 60 y.o and Older	Phase 2
Withdrawn	`NCT05430958` - Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers	Phase 1
Completed	`NCT04596579` - SARS-CoV-2 (COVID-19) Immune Surveillance Among a Population Based Sample of Adults in Florida
Completed	`NCT04405934` - COG-UK Project Hospital-Onset COVID-19 Infections Study	N/A
Enrolling by invitation	`NCT04484025` - SPI-1005 Treatment in Moderate COVID-19 Patients	Phase 2
Terminated	`NCT04442230` - NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)	Phase 2
Terminated	`NCT04642638` - Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure	Phase 2/Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Assessment of the Presence of the SARS-COV-2 Virus in the Peritoneum of COVID-19 Patients — LAPTRANSCOV

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms